US20020038149A1 - Calcium-phosphate coated implant element - Google Patents
Calcium-phosphate coated implant element Download PDFInfo
- Publication number
- US20020038149A1 US20020038149A1 US09/403,387 US40338700A US2002038149A1 US 20020038149 A1 US20020038149 A1 US 20020038149A1 US 40338700 A US40338700 A US 40338700A US 2002038149 A1 US2002038149 A1 US 2002038149A1
- Authority
- US
- United States
- Prior art keywords
- coating
- implant
- implant element
- samples
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 title claims abstract description 67
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 32
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 31
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 31
- 229960001714 calcium phosphate Drugs 0.000 title claims abstract description 25
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 25
- 238000000576 coating method Methods 0.000 claims abstract description 133
- 239000011248 coating agent Substances 0.000 claims abstract description 92
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 26
- 239000010936 titanium Substances 0.000 claims abstract description 25
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 21
- 238000004090 dissolution Methods 0.000 claims abstract description 14
- 230000035876 healing Effects 0.000 claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims abstract description 10
- 230000007774 longterm Effects 0.000 claims abstract description 9
- 238000011068 loading method Methods 0.000 claims abstract description 8
- 238000012876 topography Methods 0.000 claims abstract description 7
- 239000000560 biocompatible material Substances 0.000 claims abstract description 6
- 230000008468 bone growth Effects 0.000 claims abstract description 6
- 230000001464 adherent effect Effects 0.000 claims abstract description 4
- 238000002513 implantation Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 66
- 238000010438 heat treatment Methods 0.000 claims description 32
- 238000000151 deposition Methods 0.000 claims description 27
- 239000007789 gas Substances 0.000 claims description 26
- 230000008021 deposition Effects 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 238000001552 radio frequency sputter deposition Methods 0.000 claims description 13
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000011575 calcium Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 27
- 239000010408 film Substances 0.000 description 20
- 238000001228 spectrum Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 239000012888 bovine serum Substances 0.000 description 13
- 238000005001 rutherford backscattering spectroscopy Methods 0.000 description 13
- 238000004544 sputter deposition Methods 0.000 description 13
- 238000002441 X-ray diffraction Methods 0.000 description 12
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 12
- 238000007750 plasma spraying Methods 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000001878 scanning electron micrograph Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000608 laser ablation Methods 0.000 description 5
- 238000010883 osseointegration Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000003570 air Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005137 deposition process Methods 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 238000010884 ion-beam technique Methods 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 229960005196 titanium dioxide Drugs 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 210000002050 maxilla Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000004838 photoelectron emission spectroscopy Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000004876 x-ray fluorescence Methods 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- VVTSZOCINPYFDP-UHFFFAOYSA-N [O].[Ar] Chemical compound [O].[Ar] VVTSZOCINPYFDP-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- -1 argon ions Chemical class 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical group [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000000469 dry deposition Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000000869 ion-assisted deposition Methods 0.000 description 1
- 238000001659 ion-beam spectroscopy Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000001755 magnetron sputter deposition Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001314 profilometry Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005546 reactive sputtering Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004746 tooth root Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/58—After-treatment
- C23C14/5806—Thermal treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
- A61C8/0013—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy with a surface layer, coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/32—Phosphorus-containing materials, e.g. apatite
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/0021—Reactive sputtering or evaporation
- C23C14/0036—Reactive sputtering
- C23C14/0057—Reactive sputtering using reactive gases other than O2, H2O, N2, NH3 or CH4
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/06—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
- C23C14/08—Oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00592—Coating or prosthesis-covering structure made of ceramics or of ceramic-like compounds
- A61F2310/00796—Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
Definitions
- the invention relates to an implant element for permanent anchorage in bone tissue in which at least the surface intended to face the tissue in the implantation region is made of a biocompatible material such as titanium and having a clinically well documented surface.
- Titanium is a lightweight metal with high strength, low thermal conductivity and fine corrosion resistance. The most important property in this context is the unique bio-compatibility of titanium which might be related to the spontaneous formation of titanium oxide on its surface.
- Br ⁇ nemark System® is based on the ability of titanium to integrate permanently with bone tissue, which is a medical phenomenon named osseointegration.
- the implant screws are machined from commercially pure titanium.
- the surface topography of the machined surface shows features in the micron range.
- the interaction processes between the titanium oxide surface and the surrounding tissue which results in implant-bone integration are improved if the implant surface is micro-pitted with pits having a diameter in the range of from 10 nm up to about 1000 nm, i. e. the size of the micro-pitting approaches the order of magnitude of the cell diameter in the surrounding tissue or a few multiples thereof.
- implant screws are normally installed in the bone tissue at a first operation. Thereafter they are left unloaded for a period of three to six months covered by the soft tissue. At a second surgical session the soft tissue covering the implant screws is removed and the screws are connected to a superstructure and loading can be permitted.
- An object of the present invention is to provide an implant element which allows for a possible reduction of the healing period but which still guarantees a long term stability during clinical loading conditions.
- a further object of this invention is to increase the possibilities to use the implants more successfully also in low bone qualities, which is often the case in the maxilla and the posterior mandible.
- the implant-bone connection may be inadequate and the implant-bone structure may not withstand loading (Sennerby & Thomsen, 1993; Ohrnell et al, 1997, Branemark et al, 1997). It is therefore an urgent need to improve the treatment of patients with the osseointegrated implant technique in case of nonoptimal conditions. Such improvements may allow patients with a non-optimal, deranged and/or damaged tissue structure to benefit from treatment with osseointegrated implants.
- a suitable biocompatible material in this context is hydroxylapatite, i.e. Ca 10 (PO 4 ) 6 (OH) 2 , and mixtures of calcium-phosphates, CaP, which resemble the primary inorganic chemical constituent of bone.
- OH hydroxylapatite
- CaP calcium-phosphates
- a possible explanation for the poor long term results may be that the coatings which have been used so far normally have been plasma-sprayed to a thickness of 50-100 ⁇ m. Such coatings may have an inherent significant probability for fractures, which may be due to in vivo dissolution and the insufficient mechanical strength of the relatively thick coatings.
- the former methods include (i) plasma spraying , (ii) laser ablation, (iii) ion assisted sputtering and (iv) radio frequency (RF)-sputtering.
- the “wet” preparation techniques include: (i) dipping samples into a solution, (ii) electrolytically assisted CaP deposition and (iii) precipitation from supersaturated solutions.
- An object of our invention is to provide a substantially thinner CaP coating, since the probability for fractures will decrease with decreasing coat thickness. Therefore, the plasma spraying technique is not suitable.
- Scanning Electron Micrograph (SEM) pictures of the surface morphology produced by a typical PS deposition technique shows a rough surface on at least 50 ⁇ m scale with a large variety of appearing structures.
- the surface structure which is obtained by the PS technique is dramatically different from the structure of the underlying substrate surface, for instance a titanium surface in case of a titaniun dental implant element.
- Laser ablation is a relatively new deposition method that is able to produce a superior quality, comparatively thin high T c superconducting film coating. This method has also been used for depositing calcium-phosphate coatings.
- a typical deposition velocity is approximately 4 nm/min for an ion beam assisted sputter deposited coating, see for instance JP-PS 2562283 (Ektessabi).
- the deposition velocity of ion beam sputtered coatings is typically an order of magnitude lower (approximately 0.4 nm/min).
- the wet chemical coating methods such as dipping of samples into a sol solution, precipitation from supersturated solutions and electrolytically assisted CaP deposition techniques, are powerful methods which are well suited for use in a large scale coating fabrication, and in principle it is possible to coat also substrates with a complex shape by means of these techniques.
- each of these wet methods suffers from specific drawbacks which have to be eliminated before they can be used routinely for calcium-phosphate coating.
- the after-treatment of the coatings reported in ref.1 consists of an annealing “in air”.
- ref.3 a heating cell is used which is kept in a humid atmosphere.
- a decrease of Ca/P stochiometry upon heating from approximately 2.1 to 1.94 is reported at temperatures around 600° C.
- An object of the present invention is to provide a thin calcium phosphate coating on a clinically well documented implant element surface and which thereby combines properties for rapid bone growth during the early healing phase with the long term stability during clinical loading conditions for the well documented implant surface.
- Another object of the invention is to provide a comparatively thin coating which adheres well to the underlying implant surface, covers the surface as completely as possible and follows the implant surface morphology.
- a further object of the present invention is to provide a thin coating with a Ca/P ratio which is variable in a controlled manner. A desired crystallization of the coating would be achieved by a suitable after-treatment.
- a sputtering technique is used for providing a calcium-phosphate coating having a thickness from a few ⁇ ngström and more.
- a RF-sputtering technique is used and the coating is chemically modified by mixing the Ar-gas with oxygen and hydrogen gases resulting in a preferred Ca/P ratio.
- An annealing after-treatment of the coated implant devices is performed in a specially designed flow cell at a high temperature.
- FIG. 1 is a schematic drawing of a deposition chamber used for the RF-sputtering technique
- FIG. 2 is a schematic drawing of a mounting for the samples
- FIG. 3 is a schematic drawing of a special heating reactor for an annealing after-treatment of the coated implants
- FIGS. 4 - 17 are graphs of different surface preparations characterized by means of X-ray diffraction (XRD) technique.
- FIGS. 18 - 32 are graphs of different surface preparations characterized by means of Rutherford backscattering (RBS) technique and X-ray photoemission spectroscopy (XPS or ESCA) technique together with ion sputtering profiling, SEM pictures and FTIR technique.
- RBS Rutherford backscattering
- XPS X-ray photoemission spectroscopy
- FIG. 1 it is schematically illustrated a deposition chamber 1 in which a number of samples 2 are prepared by reactive RF-sputtering.
- the samples which are used are commercially available Br ⁇ nemark System® titanium implant screws (fixtures) sold by Nobel Biocare AB. These implants are clinically well documented and made by machining commercially pure titanium. According to the invention a thin CaP coating is deposited on this well-documented implant surface for a conditioning of the surface in order to stimulate the bonegrowth during the initial healing period.
- the thickness of the coating is in the range from a few ⁇ ngström and more.
- the composition of the calcium-phosphate coating has a Ca/P ratio which is close to stochiometric HA and the Ca/P ratio found in human bone. Such a Ca/P ratio may allow for optimal interaction between the coating and the surrounding tissue.
- HA is a complicated compound with a chemical unit formula containing 22 different atoms.
- many of the apatites can be synthesized in different crystallographic structures.
- the conditions at which HA is formed are often close enough to the formation conditions of other apatites and, as a result, a film that is formed may contain a mixture of various proportions of different apatites.
- the coating may be crystallized by means of an after-treatment at a temperature of 600° C. under humid atmosphere, see below.
- the surface morphology and roughness down to about 200 nm scale can be studied by using Scanning Electron Microscopy while the studies of the atomic scale morphology are usually performed by using Atomic Force Microscopy.
- Qualitatively the structure of a thin film can be established by using X-ray diffraction techniques, but the Transmission Electron Microscopy can also be used. The latter technique requires a substantial amount of additional sample preparation which may induce artificial modifications to a coating.
- the RF-sputtering illustrated in FIG. 1 is performed at a base pressure of approximately 10 ⁇ 6 torr and at a process pressure of approximately 10 ⁇ 3 torr.
- a target a plasma sprayed 3 mm thick HA coated Cu-holder plate 3 is used.
- the target 3 is mounted on a water cooled target holder 4 .
- the deposition chamber as well as the target holder devices are commercially available per se and will not be described in any detail here.
- Oxygen, hydrogen and argon gases were used during the reactive sputter deposition and connected to the chamber 1 via pressure regulators 5 and a shut-off valve 6 as indicated on the drawing. Gas composition, gas pressure and gas flow could all be varied independently from each other during the deposition process. The total power (power density) applied to the target could also be varied from approximately 100 W (0.55 W/cm 2 ) to about 600 W (3.3 W/cm 2 )
- the samples 2 were placed on an electrically grounded plate 12 located approximately 50 mm away from the target 3 .
- the mounting of the samples in the form of titanium fixtures are schematically illustrated in FIG. 2.
- Each fixture (implant screw) was attached to a screw holder 7 by the internal thread 8 in the upper section of the screw.
- Each holder 10 has two spikes 9 on its side, i.e. for rotation by 90° with respect to the implant screw axes.
- Five implant screw holders 10 could be mounted onto a special platelet 11 provided with two holes matching the spikes 9 on the screw holders.
- the threaded portion of 50 implant screws was in the line of sights for the sputtered material.
- each screw should be turned by 90° four times during the deposition or an automatic rotation facility could be used.
- the film thicknesses that can be produced by means of this RF-sputtering technique are limited only by practical considerations with respect to the length of the deposition time. In our examples we have an upper thickness limit of 3 ⁇ m, but it is possible to deposit thicker films if required (up to 10 ⁇ m). The method allows to deposit films down to a few ⁇ ngströms. In our examples we have a lower thickness limit of 0.1 ⁇ m (100 nm).
- composition of a coating depended mainly on the gas deposition parameters used, and varied only slightly with the power density applied to the target 3 .
- the Ca/P ratio of the coating was higher than 2 in agreement with the previously reported results from Jansen et al. This Ca/P value remained approximately constant independent from the power delivered to the target. Admixing oxygen into the carrier gas flow reduced the Ca/P ratio until it reached a value of approximately 1.68 ( ⁇ 0.05), i.e. close to a stochiometric HA.
- the film composition was weakly dependent on the power applied to the target 3 , the deposition velocity varied with the power stronger than linearly. A power of 400 W was therefore applied to the target during the deposition process. The deposition time for forming a 0.2 ⁇ m thick film coating then took approximately 30 min at the pressure(s) used.
- a special heating reactor 13 has therefore been constructed in order to anneal the samples in our case, see FIG. 3.
- the reactor consists of a 500 mm long quartz tube 14 with a heater spiral 15 wrapped around it as shown in the figure.
- the quartz tube is connected to the gas supply in the form of an Ar—H 2 O mixture via a pressure regulator 16 and a shut-off valve 17 .
- a flow controller and gas humidifier 18 are connected between the pressure regulator and the shut-off valve.
- the back-streaming of the gas from the ambient is reduced by slightly overpressuring the reactor and allowing a length of at least 400 mm behind the second shut-off valve.
- the cell is heated from the outside and the temperature is measured and regulated by a stainless steel-encapsulated thermocouple 19 which is movable inside and along the axis of the quartz tube. This allows for determination of the temperature distribution along the heated part of the reactor. Up to 40 samples (4 screw holders carrying a maximum of 10 screws each) can be heated simultaneously with maximal temperature variations of ⁇ 10° C.
- the crystallization of amorphous matters can often be divided into three stages: (i) the initial stage when stable crystallite nuclei are formed, (ii) the growth of non-overlapping crystallites and (iii) finally the growth of overlapping crystallites (Orowan ripening).
- stage (ii) the diffusional growth rate of stable nuclei increases with increasing temperature. At a given temperature on the other hand, the longer the heating time the larger is the recrystallized volume. If stage (iii) is reached, the further growth of nuclei occurs by “swallowing” of grains by other larger grains because of impingement, and the average grain size therefore increases.
- the graph in FIG. 4 represents samples deposited in pure Ar.
- the Ca/P ratio was approximately 2.
- the X-ray spectra of the untreated samples were characteristic of amorphous material with a broad feature around 30° with FWHM extending over a wide range of angles.
- the graph in FIG. 5 represents samples deposited in pure Ar and annealed in Ar+H 2 O at 600° C. for 4 h.
- XRD show that samples crystallized preferentially with a (002) reflection peak when the samples were annealed in a humid atmosphere.
- the Ca/P ratio for the samples remained high, and in addition the heat treatment introduced large and long ranged concentration gradients (according to RBS).
- the graphs in FIGS. 6 - 11 represents samples deposited in a mixture of Ar and oxygen with oxygen ranging from 5% of total gas flow to 30% of total gas flow.
- the graphs in FIGS. 16 - 17 represent samples deposited under the same conditions as in examples 3 but with varying time intervals for a subsequent heat treatment of each of the samples. Apart from further crystallization different heat treatment procedures resulted in somewhat different textures of the samples. The main changes could be described by the changes in the relation between the intensity of the (002) reflection compared to the intensity of other peaks in the spectra. Contrary to the case of pulverized HA (standard sample for XRD measurements) the intensity of the (002) reflection was dominant for the films obtained in Ar—O 2 mixtures. Actually, it carried more than 50% of the total spectral weight for all of the heat treated samples prepared using Ar—O 2 mixtures.
- FIGS. 12 and 13 represent samples deposited in a mixed flow of oxygen, hydrogen and Ar.
- the samples prepared by these mixtures differed somewhat from the samples prepared without hydrogen as can be seen in the figures.
- the graphs illustrated in FIGS. 14 and 15 represent samples deposited under the same conditions as in example 5 but with a subsequent heat treatment in Ar+H 2 O flow at 620° C. for 15 h.
- the intensity ratios of various spectral features resembled more the intensities observed in the stochiometric pulverized HA standards than did the intensities of the previously described samples.
- the relative intensity of the (002) reflection although still dominant in the untreated samples, decreased with the heat treatment, while the intensity of the reflections around 32° increased.
- the possible TCP content of the untreated samples was lower then in all of the previously described samples, i.e. the samples prepared without hydrogen. Again, the only possible non-HA reflection was the TCP-reflection seen in these samples at the 31.5°.
- the TCP content of the heat treated samples was lower then that for the samples prepared without hydrogen admixture.
- FIGS. 16 and 17 show clearly the growth of the diffracted peaks for a sample heated for 1.5 h. Further heating (for 3 h) resulted in only minor (mainly crystallographic, change of texture) changes of the spectral intensity.
- FIG. 16 shows the increase of the dominating (002) HA reflection peak upon prolonging the heat treatment.
- FIG. 17 it is seen that the spectral weight of Ti reflections decreases with the heating time, but the main changes occurs during the first hour(s) of heating. This observation has been further corroborated by two additional observations, namely by the scanning electron microscopy (SEM) experiments and by the dissolution experiments performed on the untreated and on the heat treated samples.
- SEM scanning electron microscopy
- RBS gives information on sample composition throughout the thickness of the sample.
- the depth resolution depends among other parameters on the probed depth and is typically larger than 20 nm and the compositional sensitivity is below 1 at %.
- the compositional information that can be obtained without use of spectra from standard samples is reliable to within 5%.
- ESCA combined with ion depth profiling can give compositional information with a monolayer resolution, but since various artifacts can arise during ion sputter removal of the coating (especially preferential sputtering) the results obtained with this method were cross checked by, e.g., RBS.
- Other issues that RBS is unable to give answers to are surface impurities and light element content of the sample such as carbon and hydrogen.
- FIG. 18 shows a typical RBS spectrum obtained on a sample deposited in a mixed flow of (20 ml/min) oxygen/(10 ml/min) hydrogen/(50 ml/min) argon. Along with experimental data (dots) the figure also shows the theoretical fit to the data (solid line) from which the composition of the sample can be calculated. The Ca/P ratio for this particular coating is 1.69, and the chemical formula for this coating is close to Ca 5 (PO 4 ) 3 (OH) 0.7 . As can be seen from the RBS data the composition of the sample is uniform throughout its thickness, at least within the limits of the sensitivity of the method.
- the sample would have compositional gradients, than the experimental data would exhibit additional sloping as a function of energy loss (channel number) and it would not be possible to fit the data throughout the whole energy range characteristic of a given peak (for example the gradient in calcium would appear as additional sloping starting approximately from channel 310 and continuing to approximately channel 270 , where it would be superimposed on the ions scattering off P).
- the coating shown in FIG. 18 is thick enough to completely suppress ion backscattering from the titanium substrate.
- By producing coating of different thickness in a range where Ti is visible it was possible to cross check the coat thickness obtained by using stylus profilometry with RBS, and also to calibrate the sputtering rate of the coating using ion bombardement (see the ESCA method below).
- XPS technique was used to elucidate the surface and the Ca/P ratio characterization of the coatings using compositional analysis of the spectra.
- FIG. 19 showed a typical spectrum of as deposited approximately 3 ⁇ m thick calcium-phosphate coating deposited using the same conditions as the coating shown in FIG. 18.
- the main impurity on the surfaces of as deposited coatings was always carbon.
- the carbon contamination varied between 25 at %-35 at % and depended mainly on handling of the coated surfaces.
- a careful compositional analysis of the spectra of coatings deposited at different times and using different deposition parameters revealed traces of other impurities, mainly of Si, S and Cl—about 1 at %.
- the Ca/P ratio at the surface was approximately 1.4.
- FIG. 20 shows the spectra for the sample characterized in FIG. 19, but after 0.5 h of irradiation with the ozone.
- the elemental analysis shows that carbon constitutes less than 4 at % of the surface composition.
- the Ca/P ratio increased on this almost carbon-free surface to 1.66. This suggests that either carbon predominantly binds at or close to Ca sites and thus obstructs the signal from Ca, or phosphorus is partly removed by ozone. We believe that the former possibility is the most probable one.
- FIG. 23 the Ca/P ratio has been plotted for a few coatings as obtained with RBS vs. the average bulk Ca/P ratio as determined from the ESCA by depth profiling.
- Two messages that we want to convey are: (i) some preferential sputtering does actually take place, and (ii) it is possible to obtain reliable quantitative composition of each coating from the sputter depth profile data.
- One of the aims with the present invention was to obtain smooth, well adherent coatings, without the disturbing features on a micrometer scale existing on the coatings prepared used laser ablation or plasma spraying. Moreover, we wanted to prepare coatings differing substantially with regard to dissolution velocity. It is well known that the dissolution of calcium-phosphate coatings depends strongly on a crystallinity of a coating, and on Ca/P ratio. Since we wanted to keep the Ca/P ratio constant, close to the stochiometric HA value, we decided to produce samples of different crystallinities. The crystallinity of our samples vs. after-treatment has been described in some detail in the XRD section above.
- FIG. 24 illustrates a non heat treated, 2 ⁇ m thick coating
- FIG. 25 illustrates a 2 ⁇ m thick coating heat treated for 13 h at 600° C. in the reactor described above.
- no features attributable to microcrystallite grains can be detected for the non heat treated coatings, see FIG. 24, whereas heat treated coatings exhibit crystallite with typical grain sizes around 500 nm, see FIG. 25.
- SEM pictures that the coatings do follow the morphology of the underlying substrates and that they are very smooth with no particle like features visible.
- magnification is approximately ⁇ 20000 for both pictures. Note the appearance of small crystallites on a heat treated sample. The non heat treated sample was so smooth that it was extremely difficult to obtain any contrast at these high magnifications.
- FIGS. 26 and 27 show the SEM pictures of heat treated samples also kept in bovine serum for two days (FIGS. 28 and 29) and for seven days (FIG. 30).
- FIG. 29 shows a heat treated calcium-phosphate coated sample after 2 days in bovine serum. Note that there is almost no difference compared to the heat treated samples not exposed to bovine serum shown in FIG. 25 (the magnification is approximately ⁇ 17000, i.e. of the same order as the magnification of the corresponding SEM picture shown in FIG. 25).
- FIG. 30 illustrates a heat treated sample after 7 days of exposure to bovine serum. Note that the whole surface is still covered by the calcium-phosphate coating.
- FTIR Fourier Transform Infra Red Spectroscopy
- FIG. 31 was obtained in a vacuum pumped spectrometer superior in its performance (resolution signal/noise ratio, etc.) to the other equipment used to collect data shown in FIG. 32, which operated in ambient.
- the right-hand side spectra of each figure correspond to the wavelength region where PO 4 vibrations are usually detected, while the left-hand side shows the region of the OH vibration.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Metallurgy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dentistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- The invention relates to an implant element for permanent anchorage in bone tissue in which at least the surface intended to face the tissue in the implantation region is made of a biocompatible material such as titanium and having a clinically well documented surface.
- It is previously well established to use medical implant elements for a variety of purposes. Specifically, in the dental field Brånemark System® implants for replacement of lost dental roots have been successfully used for 30 years. The treatment comprises three stages: (1) One or more titanium screws are installed in the jawbone and are left to integrate with the bone for between three and six months, (2) Special abutments are connected to the fixtures, (3) When the gums have healed, the dental prosthesis is fitted, for permanent use and providing a similar feeling as with natural teeth.
- Titanium is a lightweight metal with high strength, low thermal conductivity and fine corrosion resistance. The most important property in this context is the unique bio-compatibility of titanium which might be related to the spontaneous formation of titanium oxide on its surface. Brånemark System® is based on the ability of titanium to integrate permanently with bone tissue, which is a medical phenomenon named osseointegration.
- The implant screws are machined from commercially pure titanium. The surface topography of the machined surface shows features in the micron range. According to U.S. Pat. No. 4,330,891 the interaction processes between the titanium oxide surface and the surrounding tissue which results in implant-bone integration are improved if the implant surface is micro-pitted with pits having a diameter in the range of from 10 nm up to about 1000 nm, i. e. the size of the micro-pitting approaches the order of magnitude of the cell diameter in the surrounding tissue or a few multiples thereof.
- In addition to a well-defined implant surface topography special care also has to be taken with respect to the surgical technique to assure that the prerequisites for achieving osseointegration are fulfilled. The implant screws are normally installed in the bone tissue at a first operation. Thereafter they are left unloaded for a period of three to six months covered by the soft tissue. At a second surgical session the soft tissue covering the implant screws is removed and the screws are connected to a superstructure and loading can be permitted.
- It is assumed that such a two-stage surgical procedure with an early post-operative period without loading is important for the implant stability during the early healing phase. However, the two-stage surgical technique is a disadvantage for the patient and makes the installation time-consuming and therefore expensive. It has also been demonstrated that for specific indications a correct clinical bone anchorage can be achieved using a non-submerged approach, i.e. a one-stage surgical procedure. Also in case of such a one-stage surgical procedure it is assumed that a critical healing period, approximately three months long, during which unfavourable loading should be avoided, is important in order not to jeopardize the process of osseointegration.
- Specifically in the mandibular bone the success rate for this type of dental implants is very high. However, in the maxilla and the posterior mandible the success rate very much depend on the quality of the bone.
- An object of the present invention is to provide an implant element which allows for a possible reduction of the healing period but which still guarantees a long term stability during clinical loading conditions.
- A further object of this invention is to increase the possibilities to use the implants more successfully also in low bone qualities, which is often the case in the maxilla and the posterior mandible.
- A review of the literature shows that implant mobility and radiographic bone loss are associated with failures; either to early (primary) failures or late (secondary) failures. The early failures are the consequence of biological processes which interfere with the healing process of bone and the establishment of osseointegration. The majority of these failures are host-related, whereas late failures are the consequence of mainly overload and host-related factors. Clinical retrieval studies indicate that a high degree of bone-implant contact is a consistent finding in functioning, successful clinical osseointegrated titanium implant systems (Sennerby et al, 1991). On the other hand, ongoing studies show that clinically mobile implants with radiolucency are characterized by absence of bone and the presence of fibrous capsule formation and inflammatory cells.
- On the basis of available literature and knowledge it may therefore be concluded that the integration of titanium implants and bone and the maintenance of this integration are prerequisites for the clinically documented long-term function and relatively high success rate with this implant. However, experimental studies have shown that bone is not formed directly on the surface of the titanium implant. Instead the process of bone formation originates from existing bone surfaces and solitary islands of bone either in the bone marrow distant from the implant surface or in the distal threads. The bone formation is directed towards the titanium surface and the immediate interface zone is the last to be mineralized (Sennerby, Thomsen, Ericson, 1993a; 1993b). The early phase of bone healing is therefore of particular importance for the establishment of osseointegration. If the healing process is jeopardized, for instance by insufficient implant stability in bone of poor quality or other negative factors, such as previous irradiation of tissues or local inflammation, osteopenia and rheumatoid arthritis the implant-bone connection may be inadequate and the implant-bone structure may not withstand loading (Sennerby & Thomsen, 1993; Ohrnell et al, 1997, Branemark et al, 1997). It is therefore an urgent need to improve the treatment of patients with the osseointegrated implant technique in case of nonoptimal conditions. Such improvements may allow patients with a non-optimal, deranged and/or damaged tissue structure to benefit from treatment with osseointegrated implants.
- It is previously known that coatings of biocompatible material of controlled chemical composition and crystalline structure may be deposited onto a substrate to provide articles to be used as medical, dental or orthopedic implants. An objective of such deposition or coating is to develop an implant with a surface which provides for a stable bone-implant connection.
- An example of a suitable biocompatible material in this context is hydroxylapatite, i.e. Ca 10(PO4)6(OH)2, and mixtures of calcium-phosphates, CaP, which resemble the primary inorganic chemical constituent of bone. Various attempts have been made to deposit CaP coatings onto metal substrates in which case the CaP mixture is acting as a biocompatible coating.
- According to several scientific investigators, see for example Dhert 1992, CaP coatings may stimulate bone growth during an initial stage. However, the long term results are not convincing, see for instance Johnson B W et al (1992), Lemons J E et al (1988) and Gottlander & Albrektsson 1991.
- A possible explanation for the poor long term results may be that the coatings which have been used so far normally have been plasma-sprayed to a thickness of 50-100 μm. Such coatings may have an inherent significant probability for fractures, which may be due to in vivo dissolution and the insufficient mechanical strength of the relatively thick coatings.
- A review of the literature reveals that, in addition to the plasma spraying, there are several methods to prepare surface coatings. One way to classify these methods is to divide them into (1) those methods where a coating is prepared by “dry deposition” and (2) those methods where “wet” coating techniques are used.
- The former methods include (i) plasma spraying , (ii) laser ablation, (iii) ion assisted sputtering and (iv) radio frequency (RF)-sputtering. The “wet” preparation techniques include: (i) dipping samples into a solution, (ii) electrolytically assisted CaP deposition and (iii) precipitation from supersaturated solutions.
- None of these techniques is new per se; the principles underlying each method and the processing technologies used by each of them are in general well established and have been described in numerous publications, in particular with regard to formation of thin high T c-superconducting films, optical coatings, hard film coatings etc. These methods will therefore not be described in any detail here.
- In the following the different coating techniques will be discussed with respect to their advantages and drawbacks with respect to an implant element.
- Plasma Spraying
- Up to now plasma spraying (PS) has been by far the most commonly used method for producing CaP coatings. However, by this method only comparatively thick coatings have been produced, i.e. coatings having a thickness down to about 10 μm, but not thinner.
- An object of our invention is to provide a substantially thinner CaP coating, since the probability for fractures will decrease with decreasing coat thickness. Therefore, the plasma spraying technique is not suitable.
- Furthermore considerable amounts of impurities may be dispersed within the coating when the plasma spraying method is used in ambient air, for example an appreciable amount of carbonyls may be embedded in the CaP coating. Our invention describes an implant element which is prepared according to a well-controlled process without introduction of impurities.
- Scanning Electron Micrograph (SEM) pictures of the surface morphology produced by a typical PS deposition technique shows a rough surface on at least 50 μm scale with a large variety of appearing structures. The surface structure which is obtained by the PS technique is dramatically different from the structure of the underlying substrate surface, for instance a titanium surface in case of a titaniun dental implant element.
- Furthermore, it is usually necessary to have a rough underlying surface in order to obtain sufficient adhesion of the coating when using the PS technique. However, we can not allow for such surface roughening in the present invention since we wish to preserve the clinically well documented underlying surface.
- Laser Ablation
- Laser ablation is a relatively new deposition method that is able to produce a superior quality, comparatively thin high T c superconducting film coating. This method has also been used for depositing calcium-phosphate coatings.
- It has been illustrated that the surface of a laser ablated film is rough on the micrometer scale with a broad diameter distribution of spherical particles. Thus, the coating does not follow the underlying substrate surface morphology.
- Ion Beam Assisted Sputtering and Ion Beam Sputtering
- These techniques may be suitable for use in research, but it is virtually impossible to implement them in any larger scale for production of CaP coatings. The methods are generally expensive due to the cost of the ion guns and they are also rather slow. A typical deposition velocity is approximately 4 nm/min for an ion beam assisted sputter deposited coating, see for instance JP-PS 2562283 (Ektessabi). The deposition velocity of ion beam sputtered coatings is typically an order of magnitude lower (approximately 0.4 nm/min).
- Wet Chemical Coating Methods
- The wet chemical coating methods, such as dipping of samples into a sol solution, precipitation from supersturated solutions and electrolytically assisted CaP deposition techniques, are powerful methods which are well suited for use in a large scale coating fabrication, and in principle it is possible to coat also substrates with a complex shape by means of these techniques. However, up to date, each of these wet methods suffers from specific drawbacks which have to be eliminated before they can be used routinely for calcium-phosphate coating.
- Drawbacks with the wet chemical methods are the poor adhesion between the substrate and the coating, the low deposition velocity, difficulties to obtain films covering the entire substrate, that the apatite films consist of small sharp-edged crystallites, 2 μm-15 μm large and that the films do not appear coherent, but the grains seem to consist of piled crystallites.
- Finally, it is extremely difficult to produce a coating which is free from contaminants stemming from the impurity ions dissolved in the solutions used, e.g. Mg, Si etc. It is virtually impossible not to modify the original surface stochiometry of the substrate by the simultaneous CaP adsorption of other ions from the solution. Thus in case of coating dissolution in vivo the substrate surface exposed will not be the one which is originally used or prepared, with regard to oxide composition and surface chemistry. It should be understood that such modification of the underlying surface is not acceptable according to our objectives as it might jeopardize the long term stability conditions for the implant device in question.
- RF-Sputtering
- RF-sputtering techniques are previously described in, e.g.,
- 1. J. G. C. Wolke, K. van Dijk, H. G. Schaeken, K. de Groot and J. A. Jansen, “Study of the surface characteristics of magnetron-sputter calcium phosphate coatings”, J. of Biomedical Materials Research, 28(1994) p. 1477,
- 2. K. van Dijk, H. G. Schaeken, J. G. C. Wolke, K. de Groot and J. A. Jansen, “Influence of discharge power level on the properties of hydroxyapatite-films deposited on Ti 6Al4V with RF magnetron sputtering”, J. of Biomedical Materials Research, 29(1995) p. 269, and
- 3. K. van Dijk, H. G. Schaeken, J. G. C. Wolke and J. A. Jansen, “Influence of annealing temperature on RF magnetron sputtered calcium phosphate coatings”, Biomaterials, 17(1996) p. 405.
- These three references solely rely on physical vapour deposition. Nobel gas (Ar) is used for the RF-sputtering. When pure Ar-gas is used during the RF-sputtering process Ca/P values of approximately 2.05 (±0.15) are reported. This high Ca/P ratio is due to the fact that there occur preferential losses of e.g. POx and OH groups during the sputtering procedure (as well as during the plasma spraying and laser ablation techniques discussed above) . Such losses result in high Ca/P ratios and negligible intensities of OH-vibrations in the FTIR spectra. Thus, using pure Ar-gas during the RF-sputtering process would give Ca/P values substantially higher than pure HA and the Ca/P ratio found in human bone, i.e. Ca/P= 1.67. It should also be mentioned that the deposition velocities reported in the two first-mentioned references are 200 nm/min-250 nm/min.
- The after-treatment of the coatings reported in ref.1 consists of an annealing “in air”. In ref.3 a heating cell is used which is kept in a humid atmosphere. A decrease of Ca/P stochiometry upon heating from approximately 2.1 to 1.94 is reported at temperatures around 600° C.
- In J. E. G. Hulshoff “Osteocapacity of calcium phosphate coatings”, Thesis Catholic University Nijmegen, 1997, it is presented a coating preparation technique using RF magnetron sputtering where small amounts of water vapour or small amounts of oxygen were added to the argon (main gas carrier). However, the Ca/P ratios obtained by this coating preparation technique, see
chapter 7 in Hulshoff et al, were also substantially higher than the Ca/P ratio found in human bone. - Furthermore, we note that the FTIR spectra from the coating produced by Hulshoff et al differs significantly from previously published FTIR spectra of typical calcium phosphates, as described by e.g. P. Ducheyne, W. van Raemdonck, J. C. Heughebaert and M. Heughebaert, “Structural analysis of hydroxyapatite coatings”, Biomaterials, 7(1986) p.97, (see FIG. 7 in their article). The phosphate and hydroxyl bands, characteristic of typical calcium-phosphates and HA, seem to be absent in the FTIR spectra obtained from the coatings produced by Hulshoff et al. Specific combinations of CaP coatings with underlying substrate surfaces which would provide an optimal biological response was not presented by Hulshoff et al.
- An object of the present invention is to provide a thin calcium phosphate coating on a clinically well documented implant element surface and which thereby combines properties for rapid bone growth during the early healing phase with the long term stability during clinical loading conditions for the well documented implant surface. Another object of the invention is to provide a comparatively thin coating which adheres well to the underlying implant surface, covers the surface as completely as possible and follows the implant surface morphology. A further object of the present invention is to provide a thin coating with a Ca/P ratio which is variable in a controlled manner. A desired crystallization of the coating would be achieved by a suitable after-treatment.
- According to the invention a sputtering technique is used for providing a calcium-phosphate coating having a thickness from a few Ångström and more. Specifically, a RF-sputtering technique is used and the coating is chemically modified by mixing the Ar-gas with oxygen and hydrogen gases resulting in a preferred Ca/P ratio. An annealing after-treatment of the coated implant devices is performed in a specially designed flow cell at a high temperature.
- In the following a preferred embodiment of the invention will be more fully described with reference to the accompanying drawings in which
- FIG. 1 is a schematic drawing of a deposition chamber used for the RF-sputtering technique,
- FIG. 2 is a schematic drawing of a mounting for the samples,
- FIG. 3 is a schematic drawing of a special heating reactor for an annealing after-treatment of the coated implants,
- FIGS. 4-17 are graphs of different surface preparations characterized by means of X-ray diffraction (XRD) technique, and
- FIGS. 18-32 are graphs of different surface preparations characterized by means of Rutherford backscattering (RBS) technique and X-ray photoemission spectroscopy (XPS or ESCA) technique together with ion sputtering profiling, SEM pictures and FTIR technique.
- In FIG. 1 it is schematically illustrated a
deposition chamber 1 in which a number ofsamples 2 are prepared by reactive RF-sputtering. - The samples which are used are commercially available Brånemark System® titanium implant screws (fixtures) sold by Nobel Biocare AB. These implants are clinically well documented and made by machining commercially pure titanium. According to the invention a thin CaP coating is deposited on this well-documented implant surface for a conditioning of the surface in order to stimulate the bonegrowth during the initial healing period.
- According to the invention the thickness of the coating is in the range from a few Ångström and more. By means of the following examples it is demonstrated how such a thin coating adheres well to the underlying implant surface and covers the surface. The topographical properties of the underlying implant surface should not be affected by the coating. Since the coating is uniform and very thin, it will follow the underlying surface topography on a submicrometer scale. Thus, the clinically well documented surface topography is preserved with such a coating. The sputtering technique and the following heat treatment developed allows for a controlled variation of the crystallinity of the coating. Therefore, it is possible to control the rate of dissolution of the coating in vivo. After dissolution of the coating the originally clinically well documented surface should be maintained. As soon as the coating has made its contribution to a more rapid bone growth it is dissolved and the originally clinically well documented surface is exposed to the surrounding bone tissue.
- The composition of the calcium-phosphate coating has a Ca/P ratio which is close to stochiometric HA and the Ca/P ratio found in human bone. Such a Ca/P ratio may allow for optimal interaction between the coating and the surrounding tissue. It should be understood that HA is a complicated compound with a chemical unit formula containing 22 different atoms. There exist at least 12 related calcium phosphates differing from HA by the different Ca/P atomic ratios ranging from 2-tetracalcium phosphate, 1.67-hydroxyapatite, and to 0.5-calcium metaphosphate. In addition many of the apatites can be synthesized in different crystallographic structures. The conditions at which HA is formed are often close enough to the formation conditions of other apatites and, as a result, a film that is formed may contain a mixture of various proportions of different apatites.
- Two further aspects that influence the functional performance of a coating should be mentioned here before the sputtering technique for providing the desired coating is described, namely the morphology of the deposited CaP film coating and the crystallographic structure of the film. Both depend on the deposition technique chosen, but to some extent they can be modified by after-treatment. According to our invention the coating may be crystallized by means of an after-treatment at a temperature of 600° C. under humid atmosphere, see below.
- The surface morphology and roughness down to about 200 nm scale can be studied by using Scanning Electron Microscopy while the studies of the atomic scale morphology are usually performed by using Atomic Force Microscopy. Qualitatively the structure of a thin film can be established by using X-ray diffraction techniques, but the Transmission Electron Microscopy can also be used. The latter technique requires a substantial amount of additional sample preparation which may induce artificial modifications to a coating.
- The RF-sputtering illustrated in FIG. 1 is performed at a base pressure of approximately 10 −6 torr and at a process pressure of approximately 10 −3 torr. As a target a plasma sprayed 3 mm thick HA coated Cu-
holder plate 3 is used. Thetarget 3 is mounted on a water cooledtarget holder 4. The deposition chamber as well as the target holder devices are commercially available per se and will not be described in any detail here. - Oxygen, hydrogen and argon gases were used during the reactive sputter deposition and connected to the
chamber 1 viapressure regulators 5 and a shut-offvalve 6 as indicated on the drawing. Gas composition, gas pressure and gas flow could all be varied independently from each other during the deposition process. The total power (power density) applied to the target could also be varied from approximately 100 W (0.55 W/cm2) to about 600 W (3.3 W/cm2) - The
samples 2 were placed on an electrically groundedplate 12 located approximately 50 mm away from thetarget 3. The mounting of the samples in the form of titanium fixtures are schematically illustrated in FIG. 2. Each fixture (implant screw) was attached to ascrew holder 7 by theinternal thread 8 in the upper section of the screw. There was place for ten screws in a line in eachholder 10. Eachholder 10 has twospikes 9 on its side, i.e. for rotation by 90° with respect to the implant screw axes. Fiveimplant screw holders 10 could be mounted onto aspecial platelet 11 provided with two holes matching thespikes 9 on the screw holders. Thus at each deposition the threaded portion of 50 implant screws was in the line of sights for the sputtered material. To cover the entire threaded area each screw should be turned by 90° four times during the deposition or an automatic rotation facility could be used. - The film thicknesses that can be produced by means of this RF-sputtering technique are limited only by practical considerations with respect to the length of the deposition time. In our examples we have an upper thickness limit of 3 μm, but it is possible to deposit thicker films if required (up to 10 μm). The method allows to deposit films down to a few Ångströms. In our examples we have a lower thickness limit of 0.1 μm (100 nm).
- It was found that the composition of a coating depended mainly on the gas deposition parameters used, and varied only slightly with the power density applied to the
target 3. For example if only Ar was used as a carrier gas during the deposition process, the Ca/P ratio of the coating was higher than 2 in agreement with the previously reported results from Jansen et al. This Ca/P value remained approximately constant independent from the power delivered to the target. Admixing oxygen into the carrier gas flow reduced the Ca/P ratio until it reached a value of approximately 1.68 (±0.05), i.e. close to a stochiometric HA. This value remained constant for oxygen to argon flow ratios between 10% and 40% of the total gas flow (O2 flow between 5 ml/min to 20 ml/min admixed with 50 ml/min Ar). Admixing additional hydrogen flow to oxygen argon mixtures (H2 flow between 5 ml/min to 20 ml/min) did not produce noticeable differencies in the Ca/P composition, but did change the FTIR spectra. - For a given gas composition and flow the total gas pressure in the
sputter chamber 1 produced only minor changes in the stochiometry of the coating. The general tendency was that an increasing total pressure at a given flow increased the Ca/P ratio. - Although the film composition was weakly dependent on the power applied to the
target 3, the deposition velocity varied with the power stronger than linearly. A power of 400 W was therefore applied to the target during the deposition process. The deposition time for forming a 0.2 μm thick film coating then took approximately 30 min at the pressure(s) used. - It has been observed previously by Jansen et al. that the coatings produced by RF-sputtering were amorphous, i.e. they either did not produce a well resolved diffraction peaks in X-ray experiments, or the diffracted peaks were superimposed with a characteristic “slopy” background. To crystallize the deposited films a treatment has to be performed after the deposition process. A conventional treatment consists of heating the samples in air to temperatures of up to 1000° C. However, heating in air introduces, an appreciable amount of impurities into the bulk, mainly various C—O compounds. Use of such high temperatures often results in a partial peeling off of the films.
- A
special heating reactor 13 has therefore been constructed in order to anneal the samples in our case, see FIG. 3. The reactor consists of a 500 mmlong quartz tube 14 with aheater spiral 15 wrapped around it as shown in the figure. The quartz tube is connected to the gas supply in the form of an Ar—H2O mixture via apressure regulator 16 and a shut-offvalve 17. A flow controller andgas humidifier 18 are connected between the pressure regulator and the shut-off valve. The back-streaming of the gas from the ambient is reduced by slightly overpressuring the reactor and allowing a length of at least 400 mm behind the second shut-off valve. The cell is heated from the outside and the temperature is measured and regulated by a stainless steel-encapsulatedthermocouple 19 which is movable inside and along the axis of the quartz tube. This allows for determination of the temperature distribution along the heated part of the reactor. Up to 40 samples (4 screw holders carrying a maximum of 10 screws each) can be heated simultaneously with maximal temperature variations of ±10° C. - The crystallization of amorphous matters can often be divided into three stages: (i) the initial stage when stable crystallite nuclei are formed, (ii) the growth of non-overlapping crystallites and (iii) finally the growth of overlapping crystallites (Orowan ripening). There are two important parameters that are governing all the three stages and which can be externally selected: the temperature of the sample and the total time during which the sample is heated. In the first stage it is the temperature and the balance of the free energy difference between the crystalline vs. the amorphous state of the material that govern the critical size for nuclei stability and their density. At higher temperatures fewer stable nuclei are formed and therefore the onset of stage (iii), i.e. the overlapping of nuclei, occurs at a larger average grain size compared with lower temperatures. Also, it is usually observed during stage (ii) that the diffusional growth rate of stable nuclei increases with increasing temperature. At a given temperature on the other hand, the longer the heating time the larger is the recrystallized volume. If stage (iii) is reached, the further growth of nuclei occurs by “swallowing” of grains by other larger grains because of impingement, and the average grain size therefore increases.
- By means of visual observation it has been found that for temperatures higher then 650° C. the samples became discolored, and for some of the samples the coating peeled off from the titanium substrates. These findings then were in agreement with the findings of Jansen et al. Therefore, all the crystallizations have been performed at a temperature of 600° C. in our case.
- The X-ray diffraction of the samples heated to a temperature of 600° C. for different time intervals showed that the total intensity of the diffracted X-rays increased with time in the time interval of 0.5 h-6 h after which the increase in intensity levelled off. Thus it is possible to vary the crystallinity of the coating and therefore its dissolution properties in vivo by varying the time for heat treatment with constant temperature.
- In the following some examples of preparations will be described with reference to the graphs illustrated in FIGS. 4-17. In these examples the XRD spectra were obtained for samples prepared using different deposition conditions with respect to gas composition and subject to different heat treatments after the deposition.
- The experimental conditions at which each of the samples presented in the subsequent figures was prepared are given within each figure. The following sample conditions will be described:
- (i) deposition in pure Ar;
- (ii) deposition in pure Ar and subsequent heat treatment;
- (iii) deposition using mixtures of Ar and oxygen during RF-sputtering with oxygen ranging from 5% of total gas flow to 30% of total gas flow;
- (iv) subsequent heat treatment of each of the samples;
- (v) samples deposited in a mixed flow of oxygen, hydrogen and Ar (12% H 2, 25% O2);
- (vi) heat treatment of these samples;
- The graph in FIG. 4 represents samples deposited in pure Ar. The Ca/P ratio was approximately 2. The X-ray spectra of the untreated samples were characteristic of amorphous material with a broad feature around 30° with FWHM extending over a wide range of angles.
- The graph in FIG. 5 represents samples deposited in pure Ar and annealed in Ar+H 2O at 600° C. for 4 h. XRD show that samples crystallized preferentially with a (002) reflection peak when the samples were annealed in a humid atmosphere. According to both XPS and RBS (see below) the Ca/P ratio for the samples remained high, and in addition the heat treatment introduced large and long ranged concentration gradients (according to RBS).
- The graphs in FIGS. 6-11 represents samples deposited in a mixture of Ar and oxygen with oxygen ranging from 5% of total gas flow to 30% of total gas flow. Although there was no indication of grain structure in the scanning electron microscope investigation of the samples (see FIG. 24 below) down to grain sizes well below 100 nm, the XRD on the prepared samples did show diffraction peaks that differed for different sputter conditions. Although most of the peaks could be assigned to HA a closer inspection showed that both samples deposited in 5% oxygen flow and in 20% oxygen flow contained some TCP. It is virtually impossible to give an estimate of the amount of TCP in these samples because quantification of XRD spectra from foils or thin films is in general not possible. Evaluating the intensity ratios of peaks that can be assigned to TCP and to the HA in FIGS. 7 and 11 will only give an upper ratio on the TCP content of approximately 15% and 30% for the samples shown in FIGS. 7 and 11, respectively. The samples prepared using 15% of oxygen in Ar contained less than 10% of TCP using the same evaluation procedure. The only distinguishable TCP reflection seen in all these samples was one at 31.5°.
- The graphs in FIGS. 16-17 represent samples deposited under the same conditions as in examples 3 but with varying time intervals for a subsequent heat treatment of each of the samples. Apart from further crystallization different heat treatment procedures resulted in somewhat different textures of the samples. The main changes could be described by the changes in the relation between the intensity of the (002) reflection compared to the intensity of other peaks in the spectra. Contrary to the case of pulverized HA (standard sample for XRD measurements) the intensity of the (002) reflection was dominant for the films obtained in Ar—O2 mixtures. Actually, it carried more than 50% of the total spectral weight for all of the heat treated samples prepared using Ar—O2 mixtures.
- Note the decrease in the intensity of the reflections due to Ti substrate with increased heating time as shown in FIG. 17. The decrease of the substrate signal is due to the fact that the degree of crystallinity of the coating increases and causes a larger portion of the X-ray intensity to be channeled by the reflections from the coating.
- The graphs illustrated in FIGS. 12 and 13 represent samples deposited in a mixed flow of oxygen, hydrogen and Ar. The samples prepared by these mixtures differed somewhat from the samples prepared without hydrogen as can be seen in the figures.
- The graphs illustrated in FIGS. 14 and 15 represent samples deposited under the same conditions as in example 5 but with a subsequent heat treatment in Ar+H 2O flow at 620° C. for 15 h. After heat treatment the intensity ratios of various spectral features resembled more the intensities observed in the stochiometric pulverized HA standards than did the intensities of the previously described samples. Thus the relative intensity of the (002) reflection, although still dominant in the untreated samples, decreased with the heat treatment, while the intensity of the reflections around 32° increased. The possible TCP content of the untreated samples was lower then in all of the previously described samples, i.e. the samples prepared without hydrogen. Again, the only possible non-HA reflection was the TCP-reflection seen in these samples at the 31.5°. The TCP content of the heat treated samples was lower then that for the samples prepared without hydrogen admixture.
- Heat treatment clearly increased the degree of crystallinity of the samples. Quantitatively the degree of crystallization cannot be assessed from the XRD spectra since the spectra from thin films are not amenible to quantitative analysis. Qualitatively however, the XRD results shown in FIGS. 16 and 17 show clearly the growth of the diffracted peaks for a sample heated for 1.5 h. Further heating (for 3 h) resulted in only minor (mainly crystallographic, change of texture) changes of the spectral intensity. FIG. 16 shows the increase of the dominating (002) HA reflection peak upon prolonging the heat treatment. In FIG. 17 it is seen that the spectral weight of Ti reflections decreases with the heating time, but the main changes occurs during the first hour(s) of heating. This observation has been further corroborated by two additional observations, namely by the scanning electron microscopy (SEM) experiments and by the dissolution experiments performed on the untreated and on the heat treated samples.
- We have therefore concluded that heating at a temperature of 600° C. for 15 h was sufficient to produce full crystallization of the films, and that the only result of further treatment (if any) would possibly produce increased grain sizes within the films.
- In addition to the described XRD surface characterizations, characterizatins of the Ca/P ratio have been performed by using two different methods: Rutherford backscattering (RBS) and X-ray photoemission spectroscopy (XPS or ESCA) together with ion sputter profiling, see FIGS. 18-23. Each method is well established and will not be described here in any detail.
- RBS gives information on sample composition throughout the thickness of the sample. The depth resolution depends among other parameters on the probed depth and is typically larger than 20 nm and the compositional sensitivity is below 1 at %. However, the compositional information that can be obtained without use of spectra from standard samples is reliable to within 5%. ESCA combined with ion depth profiling can give compositional information with a monolayer resolution, but since various artifacts can arise during ion sputter removal of the coating (especially preferential sputtering) the results obtained with this method were cross checked by, e.g., RBS. Other issues that RBS is unable to give answers to are surface impurities and light element content of the sample such as carbon and hydrogen.
- FIG. 18 shows a typical RBS spectrum obtained on a sample deposited in a mixed flow of (20 ml/min) oxygen/(10 ml/min) hydrogen/(50 ml/min) argon. Along with experimental data (dots) the figure also shows the theoretical fit to the data (solid line) from which the composition of the sample can be calculated. The Ca/P ratio for this particular coating is 1.69, and the chemical formula for this coating is close to Ca 5(PO4)3(OH)0.7. As can be seen from the RBS data the composition of the sample is uniform throughout its thickness, at least within the limits of the sensitivity of the method. If the sample would have compositional gradients, than the experimental data would exhibit additional sloping as a function of energy loss (channel number) and it would not be possible to fit the data throughout the whole energy range characteristic of a given peak (for example the gradient in calcium would appear as additional sloping starting approximately from channel 310 and continuing to approximately channel 270, where it would be superimposed on the ions scattering off P).
- It can also be seen that the coating shown in FIG. 18 is thick enough to completely suppress ion backscattering from the titanium substrate. By producing coating of different thickness in a range where Ti is visible it was possible to cross check the coat thickness obtained by using stylus profilometry with RBS, and also to calibrate the sputtering rate of the coating using ion bombardement (see the ESCA method below).
- XPS technique was used to elucidate the surface and the Ca/P ratio characterization of the coatings using compositional analysis of the spectra.
- FIG. 19 showed a typical spectrum of as deposited approximately 3 μm thick calcium-phosphate coating deposited using the same conditions as the coating shown in FIG. 18. As can be seen from the figure the main impurity on the surfaces of as deposited coatings was always carbon. The carbon contamination varied between 25 at %-35 at % and depended mainly on handling of the coated surfaces. A careful compositional analysis of the spectra of coatings deposited at different times and using different deposition parameters revealed traces of other impurities, mainly of Si, S and Cl—about 1 at %. As can be deducted from the compositional analysis of the spectra in FIG. 19 the Ca/P ratio at the surface was approximately 1.4.
- The carbon contamination on the surface could be easily removed by irradiating samples with UV produced ozone. This is illustrated in FIG. 20 which shows the spectra for the sample characterized in FIG. 19, but after 0.5 h of irradiation with the ozone. The elemental analysis shows that carbon constitutes less than 4 at % of the surface composition. The Ca/P ratio increased on this almost carbon-free surface to 1.66. This suggests that either carbon predominantly binds at or close to Ca sites and thus obstructs the signal from Ca, or phosphorus is partly removed by ozone. We believe that the former possibility is the most probable one.
- We have controlled that the almost carbon-clean calcium-phosphate surface remained reasonably clean for at least 10 min in air, and therefore used the ozone cleaning before the in-vivo use of implants.
- The carbon contamination increased somewhat during heat aftertreatment, and some carbon containing species diffused into the bulk. However, the amount of carbon in the bulk as determined using sputter ion depth profiling never exceeded 5 at %.
- To investigate the Ca/P ratio in the bulk of the film we have collected ESCA spectra after subsequent time intervals (either 2 min or 5 min) during which the film under investigation has been bombarded by Ar-ions. ESCA spectra were collected over energy intervals of: O 1s, Ca 2p, P 2p, C 1s and Ti 2p peaks. An example of such depth profile spectra is shown in FIG. 21. The compositional analysis of these spectra with regard to the Ca/P ratio illustrates a typical composition profile vs. depth of the coating and is shown in FIG. 22. After an initial increase due to the above mentioned carbon surface contamination (this particular sample was not subject to ozone treatment) the Ca/P ratio remains constant at approximately 1.65 (±0.07). This was typical of all samples prepared by us, also of the ones which underwent an after-treatment. Note that the Ca/P ratio stabilizes only after sputtering for approximately 10 min. This effect is partly due to the smearing of the surface carbon contamination within a few nm inside the coating by bombarding ions, but can also arise if one of the species is sputtered preferentially by the argon ions. The detected surface composition would then change until equilibrium has been reached between the amount of the preferentially sputtered species remaining at the surface and the fraction of these species “uncovered” by the ion beam. Since some preferential sputtering does take place during calcium-phosphate sputtering we believe that both processes are at work.
- In FIG. 23 the Ca/P ratio has been plotted for a few coatings as obtained with RBS vs. the average bulk Ca/P ratio as determined from the ESCA by depth profiling. Two messages that we want to convey are: (i) some preferential sputtering does actually take place, and (ii) it is possible to obtain reliable quantitative composition of each coating from the sputter depth profile data.
- One of the aims with the present invention was to obtain smooth, well adherent coatings, without the disturbing features on a micrometer scale existing on the coatings prepared used laser ablation or plasma spraying. Moreover, we wanted to prepare coatings differing substantially with regard to dissolution velocity. It is well known that the dissolution of calcium-phosphate coatings depends strongly on a crystallinity of a coating, and on Ca/P ratio. Since we wanted to keep the Ca/P ratio constant, close to the stochiometric HA value, we decided to produce samples of different crystallinities. The crystallinity of our samples vs. after-treatment has been described in some detail in the XRD section above. This discussion can be summarized as follows: as deposited coatings were not fully amorphous, but heating in a flow of Ar saturated with water vapour increased the degree of crystallinity of the coatings substantially by increasing the size of crystallites as well as their density. This can be seen in electron micrograph (SEM) pictures taken from non heat treated as well as heat treated coatings as shown in FIGS. 24 and 25, respectively. FIG. 24 illustrates a non heat treated, 2 μm thick coating, while FIG. 25 illustrates a 2 μm thick coating heat treated for 13 h at 600° C. in the reactor described above. As can be seen no features attributable to microcrystallite grains can be detected for the non heat treated coatings, see FIG. 24, whereas heat treated coatings exhibit crystallite with typical grain sizes around 500 nm, see FIG. 25. It is also clear from the SEM pictures that the coatings do follow the morphology of the underlying substrates and that they are very smooth with no particle like features visible.
- The magnification is approximately ×20000 for both pictures. Note the appearance of small crystallites on a heat treated sample. The non heat treated sample was so smooth that it was extremely difficult to obtain any contrast at these high magnifications.
- To investigate the dissolution of our samples we have immersed the as prepared and heat treated samples, respectively, into a bovine serum solution for different time periods (2 days, 5 days and 7 days) and analyzed each sample using XPS and SEM. The XPS spectra of as deposited, i.e. non heat treated, samples immersed into bovine serum for 5 days indicated that the surface was “patchy”. There were islands of calcium-phosphate film while other parts of the substrate surface were almost completely bare. The thickness of the remaining calcium-phosphate patches seemed to have decreased dramatically. The heat treated samples subjected to similar bovine serum exposure, on the other hand, showed a minor decrease of film thickness but the effect was too small to be quantifiable by sputter depth profiling.
- To further corroborate these results we have investigated the same samples exposed to bovine serum by SEM. The results for non-heat treated samples are shown in FIGS. 26 and 27 (for two days and seven days, respectively) while FIGS. 28, 29 and 30 show the SEM pictures of heat treated samples also kept in bovine serum for two days (FIGS. 28 and 29) and for seven days (FIG. 30).
- After only two days in bovine serum the initially smooth and continuous non heat treated coating starts to dissolve. As can be seen in FIG. 26 the coating has partly dissolved from the surface already after two days. Note that the feature on the right hand side in FIG. 26 is the bare Ti-surface. The left hand side shows a “cracky” and smooth surface with featureless grains which is a remnant of the calcium-phosphate coating.
- After seven days of exposure to bovine serum yarn-like, fluffy features which contained Ca and P (according to X-ray fluorescence analysis) appeared on a few spots. The “original” coating had disappeared, see FIG. 27.
- The SEM pictures of heat treated samples in FIGS. 28-30 show only minor differences between the unexposed samples and the samples exposed to bovine serum, respectively. The main difference was that we could detect dendrite-like features on top of the coating on a few parts of the samples exposed to bovine serum after 5 days (not shown). X-ray fluorescence analysis showed that such features mainly consisted of calcium and phosphorous. The features had developed into “humps” after 7 days of exposure to bovine serum as seen in a lower part of FIG. 30.
- FIG. 29 shows a heat treated calcium-phosphate coated sample after 2 days in bovine serum. Note that there is almost no difference compared to the heat treated samples not exposed to bovine serum shown in FIG. 25 (the magnification is approximately ×17000, i.e. of the same order as the magnification of the corresponding SEM picture shown in FIG. 25).
- FIG. 30 illustrates a heat treated sample after 7 days of exposure to bovine serum. Note that the whole surface is still covered by the calcium-phosphate coating.
- Finally, a characterization of the prepared calcium-phosphate coatings have been performed by means of Fourier Transform Infra Red Spectroscopy (FTIR) technique. The chemical component unique for hydroxyapatite compared with other calcium-phosphates is the OH-group. Other phosphates do contain hydrogen too, but as a chemically different specie. For example hydrogen in the dicalcium phosphate is not bonded to oxygen but constitutes rather a “chemical link” between the Ca and the PO 4 group. The FTIR technique enables one to detect many of the characteristic vibrations for a given compound, and in particular OH. It is not a quantitative technique and the amplitude of a particular OH-vibration cannot easily be compared between differently prepared samples having identical composition (for example the reflectivity, and thus the signal level will vary with surface roughness differently for different wave-lengths used in FTIR). Neither can the intensities of the same spectral feature of two identical samples obtained using two different equipments be compared with each other. Nevertheless it is useful to elucidate general trends, and compare features obtained using the same equipment not too far separated in wavelength. Here two FTIR spectra are presented: one of the non heat treated sample, FIG. 31, and another for the heat treated sample, FIG. 32. The spectrum in FIG. 31 was obtained in a vacuum pumped spectrometer superior in its performance (resolution signal/noise ratio, etc.) to the other equipment used to collect data shown in FIG. 32, which operated in ambient. The right-hand side spectra of each figure correspond to the wavelength region where PO4 vibrations are usually detected, while the left-hand side shows the region of the OH vibration. These results can be compared to the data available in the literature, particularly with the data of P. Ducheyne, W. van Raedmonck, J. C. Heughebaert and M. Heughebaert, Biomaterials, 7(1986) p.97, mentioned earlier. In FIG. 7 of the Ducheyne et al article the authors analyze the FTIR spectra of various calcium phosphates. From the comparison of our spectra in FIGS. 31 and 32 with their results we can conclude that our coating consist to a large extent of the defect-free hydroxyapatite.
- The examples above indicate that it is possible to produce thin CaP coatings with well defined chemical properties close to stochiometric HA. We have shown that such coatings have well controlled crystallographic properties, which can be varied within the range from nearly amorphous to nearly fully crystallized with the heat treatment method described. The in-vivo degradation of such coatings can be well controlled, since the dissolution rate depends strongly on the degree of crystallinity. Thus, the underlying long-term clinically well documented surface will be exposed after the coating has dissolved during the initial healing phase. Pre-clinical in-vivo data indicate that such coatings may have a substantial effect on the interaction process between the coating and the surrounding tissue. The biological verification of the hypothesis that a combination of a thin calcium-phosphate coating and an underlying clinically well-documented surface with micro-pitted topography would promote a significantly higher bone-implant contact than a non-coated surface was evident in a series of studies in rabbits. The animals were followed for six weeks. In both cortical and trabecular bone it was found that mineralized bone was in greater contact with the implant surfaces with a less than 2 micron thick calcium-phosphate coating than with the non-coated titanium surface.
- In vitro data indicates that the coating is resorbable and has a predetermined dissolution rate. This makes it possible to predict for a coated implant element a specific time period under which the coating is active. After that time period the coating has been disappeared and the underlying surface is exposed.
- Therefore it is possible to vary the implant element according to the indicated technical parameters and provide time-programmed surfaces. The biological effects of calcium-phosphate/titanium-oxide programmed surfaces is indicated by the present biological results where differences in bone formation distant to the implant surface, (but within threads), may be modulated depending on the crystallinity of the calcium-phosphate coating.
- The invention is not limited to the specific methods and embodiments that has been illustrated so far but can be varied within the scope of the accompanying claims.
Claims (7)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9701647 | 1997-04-30 | ||
| SE9701647-1 | 1997-04-30 | ||
| SE9701647A SE9701647D0 (en) | 1997-04-30 | 1997-04-30 | Calcium-phonsphate coated implant element |
| PCT/SE1998/000787 WO1998048862A1 (en) | 1997-04-30 | 1998-04-29 | Calcium-phosphate coated implant element |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20020038149A1 true US20020038149A1 (en) | 2002-03-28 |
| US6419708B1 US6419708B1 (en) | 2002-07-16 |
Family
ID=20406803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/403,387 Expired - Lifetime US6419708B1 (en) | 1997-04-30 | 1998-04-29 | Calcium-phosphate coated implant element |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6419708B1 (en) |
| EP (1) | EP0980272A1 (en) |
| AU (1) | AU736802B2 (en) |
| CA (1) | CA2288150A1 (en) |
| SE (1) | SE9701647D0 (en) |
| WO (1) | WO1998048862A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040236338A1 (en) * | 2001-07-04 | 2004-11-25 | Jan Hall | Implant |
| WO2005089829A2 (en) | 2004-03-10 | 2005-09-29 | Scil Technology Gmbh | Coated implants, their manufacturing and use thereof |
| US20060100716A1 (en) * | 2002-06-27 | 2006-05-11 | Reto Lerf | Open-pored metal coating for joint replacement implants and method for production thereof |
| US20080241350A1 (en) * | 2007-03-26 | 2008-10-02 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase |
| US20080241570A1 (en) * | 2007-03-26 | 2008-10-02 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase and such medical component |
| US20090088858A1 (en) * | 2004-12-23 | 2009-04-02 | Plus Orthopedics Ag | Method Of Surface Finishing A Bone Implant |
| US20090324442A1 (en) * | 2007-03-26 | 2009-12-31 | Howmedica Osteonics Corp. | Method for fabricating a biocompatible material having a high carbide phase and such material |
| WO2009118531A3 (en) * | 2008-03-26 | 2010-07-15 | Eminate Ltd | Medical devices |
| US9017055B2 (en) | 2012-07-12 | 2015-04-28 | Biomet Manufacturing, Llc | Device for coating intramedullary rods with cement |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE514323C2 (en) | 1999-05-31 | 2001-02-12 | Nobel Biocare Ab | Implants and procedure and use in implants |
| SE515695C2 (en) * | 1999-05-31 | 2001-09-24 | Nobel Biocare Ab | Implant with coating of bone growth stimulant for bone application and procedure in such implant |
| JP2001192853A (en) * | 1999-10-29 | 2001-07-17 | Matsumoto Shika Univ | Method for forming oxide film on metal member for bonding and method for bonding metal member |
| DE10006992B4 (en) * | 2000-02-16 | 2006-10-12 | Aesculap Ag & Co. Kg | Process for coating an implant and implant with coating |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| SE519564C2 (en) * | 2001-07-04 | 2003-03-11 | Nobel Biocare Ab | Implants, for example dental implants, coated with bone growth stimulants |
| CN100366300C (en) * | 2001-10-11 | 2008-02-06 | 斯特劳曼控股公司 | Bone-seeking implant |
| SE520731C2 (en) | 2001-12-28 | 2003-08-19 | Nobel Biocare Ab | Device applicable in connection with bone and / or tissue in human body and method and use thereof |
| US20040053197A1 (en) * | 2002-09-16 | 2004-03-18 | Zoran Minevski | Biocompatible implants |
| US7067169B2 (en) * | 2003-06-04 | 2006-06-27 | Chemat Technology Inc. | Coated implants and methods of coating |
| DE102005052354A1 (en) * | 2005-11-02 | 2007-05-03 | Plus Orthopedics Ag | Open-pore biocompatible surface layer for application to an implant comprises a coherent pore network and has a defined surface area |
| ES2726355T3 (en) | 2005-11-14 | 2019-10-03 | Biomet 3I Llc | Deposition of discrete nanoparticles on an implant surface |
| US20070158446A1 (en) * | 2006-01-05 | 2007-07-12 | Howmedica Osteonics Corp. | Method for fabricating a medical implant component and such component |
| US8187660B2 (en) * | 2006-01-05 | 2012-05-29 | Howmedica Osteonics Corp. | Method for fabricating a medical implant component and such component |
| US20070156249A1 (en) * | 2006-01-05 | 2007-07-05 | Howmedica Osteonics Corp. | High velocity spray technique for medical implant components |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| JP5806466B2 (en) | 2008-01-28 | 2015-11-10 | バイオメット・3アイ・エルエルシー | Implant surface with improved hydrophilicity |
| CN105963781A (en) * | 2008-02-29 | 2016-09-28 | 史密夫和内修有限公司 | Coating and coating method |
| JP2011512957A (en) * | 2008-02-29 | 2011-04-28 | スミス アンド ネフュー インコーポレーテッド | Gradient coating for biomedical applications |
| US8906817B2 (en) | 2009-01-12 | 2014-12-09 | National Taiwan University | Sintered calcium sulfate ceramic material and sinterable calcium sulfate ceramic material |
| RU2400423C1 (en) * | 2009-06-02 | 2010-09-27 | Государственное образовательное учреждение высшего профессионального образования "Томский политехнический университет" | Method of obtaining calcium phosphate coating on sample |
| US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
| CN103313733A (en) | 2010-11-15 | 2013-09-18 | 捷迈整形外科生物材料有限公司 | Bone void fillers |
| ES2671740T3 (en) | 2012-03-20 | 2018-06-08 | Biomet 3I, Llc | Treatment surface for an implant surface |
| KR101296591B1 (en) * | 2012-04-20 | 2013-08-14 | 오스템임플란트 주식회사 | Post treatment device for ha coating layer of dental implant surface |
| GB2523828A (en) | 2014-03-07 | 2015-09-09 | Nobel Biocare Services Ag | Dental implant |
| GB2523827A (en) | 2014-03-07 | 2015-09-09 | Nobel Biocare Services Ag | Dental implant |
| CN103993315B (en) * | 2014-06-05 | 2016-03-23 | 山东大学 | A Preparation Technology of CaP-TiO2 Composite Biofilm |
| US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
| US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416175B (en) | 1979-03-07 | 1980-12-08 | Per Ingvar Branemark | FOR IMPLANTATION IN BODY TISSUE Separate Bone Tissue, Dedicated Material |
| JPS62120403A (en) * | 1985-11-20 | 1987-06-01 | Permelec Electrode Ltd | Titanium composite body having porous surface and its manufacture |
| JPS6399867A (en) * | 1986-10-17 | 1988-05-02 | ペルメレツク電極株式会社 | Composite material coated with calcium phosphate and its production |
| US4944754A (en) | 1987-04-29 | 1990-07-31 | Vent-Plant Corporation | Method of manufacturing synthetic bone coated surgical implants |
| US5164187A (en) * | 1990-04-05 | 1992-11-17 | Norian Corporation | Hydroxyapatite prosthesis coatings |
| US5205921A (en) * | 1991-02-04 | 1993-04-27 | Queen's University At Kingston | Method for depositing bioactive coatings on conductive substrates |
| US5258044A (en) * | 1992-01-30 | 1993-11-02 | Etex Corporation | Electrophoretic deposition of calcium phosphate material on implants |
| JPH06105900A (en) * | 1992-09-22 | 1994-04-19 | Mitsubishi Materials Corp | Bioactive ceramic coated implant |
| WO1994025637A1 (en) * | 1993-04-23 | 1994-11-10 | Etex Corporation | Method of coating medical devices and devices coated thereby |
| SE504294C2 (en) * | 1993-10-01 | 1996-12-23 | Lucocer Ab | Implants intended to be fixed by contact with newly formed bone tissue |
| CA2142636C (en) * | 1994-02-18 | 2005-09-20 | Salvatore Caldarise | Implantable articles with as-cast macrotextured surface regions and method of manufacturing the same |
| US5947893A (en) * | 1994-04-27 | 1999-09-07 | Board Of Regents, The University Of Texas System | Method of making a porous prothesis with biodegradable coatings |
| US6027742A (en) * | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| ATE235927T1 (en) * | 1996-05-10 | 2003-04-15 | Isotis Nv | DEVICE FOR RECEIVING AND RELEASING BIOLOGICALLY ACTIVE SUBSTANCES |
-
1997
- 1997-04-30 SE SE9701647A patent/SE9701647D0/en unknown
-
1998
- 1998-04-29 EP EP98920802A patent/EP0980272A1/en not_active Withdrawn
- 1998-04-29 CA CA002288150A patent/CA2288150A1/en not_active Abandoned
- 1998-04-29 US US09/403,387 patent/US6419708B1/en not_active Expired - Lifetime
- 1998-04-29 WO PCT/SE1998/000787 patent/WO1998048862A1/en not_active Ceased
- 1998-04-29 AU AU73555/98A patent/AU736802B2/en not_active Ceased
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040236338A1 (en) * | 2001-07-04 | 2004-11-25 | Jan Hall | Implant |
| US20060100716A1 (en) * | 2002-06-27 | 2006-05-11 | Reto Lerf | Open-pored metal coating for joint replacement implants and method for production thereof |
| WO2005089829A2 (en) | 2004-03-10 | 2005-09-29 | Scil Technology Gmbh | Coated implants, their manufacturing and use thereof |
| US20090088858A1 (en) * | 2004-12-23 | 2009-04-02 | Plus Orthopedics Ag | Method Of Surface Finishing A Bone Implant |
| US20100042223A9 (en) * | 2004-12-23 | 2010-02-18 | Plus Orthopedics Ag | Method Of Surface Finishing A Bone Implant |
| US8920534B2 (en) | 2007-03-26 | 2014-12-30 | Howmedica Osteonics Corp. | Method for fabricating a biocompatible material having a high carbide phase and such material |
| US20090324442A1 (en) * | 2007-03-26 | 2009-12-31 | Howmedica Osteonics Corp. | Method for fabricating a biocompatible material having a high carbide phase and such material |
| US20080241570A1 (en) * | 2007-03-26 | 2008-10-02 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase and such medical component |
| US7771775B2 (en) | 2007-03-26 | 2010-08-10 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase |
| US8057914B2 (en) | 2007-03-26 | 2011-11-15 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase and such medical component |
| US20080241350A1 (en) * | 2007-03-26 | 2008-10-02 | Howmedica Osteonics Corp. | Method for fabricating a medical component from a material having a high carbide phase |
| US9776246B2 (en) | 2007-03-26 | 2017-10-03 | Howmedica Osteonics Corp. | Method for fabricating a biocompatible material having a high carbide phase and such material |
| WO2009118531A3 (en) * | 2008-03-26 | 2010-07-15 | Eminate Ltd | Medical devices |
| US20110022178A1 (en) * | 2008-03-26 | 2011-01-27 | David Malcolm Grant | Medical devices |
| US9017055B2 (en) | 2012-07-12 | 2015-04-28 | Biomet Manufacturing, Llc | Device for coating intramedullary rods with cement |
| US9440379B2 (en) | 2012-07-12 | 2016-09-13 | Biomet Manufacturing, Llc | Device for coating intramedullary rods with cement |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2288150A1 (en) | 1998-11-05 |
| AU736802B2 (en) | 2001-08-02 |
| AU7355598A (en) | 1998-11-24 |
| US6419708B1 (en) | 2002-07-16 |
| EP0980272A1 (en) | 2000-02-23 |
| WO1998048862A1 (en) | 1998-11-05 |
| SE9701647D0 (en) | 1997-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6419708B1 (en) | Calcium-phosphate coated implant element | |
| US4908030A (en) | Method of manufacturing synthetic bone coated surgical implants | |
| US4944754A (en) | Method of manufacturing synthetic bone coated surgical implants | |
| Barrere et al. | Influence of ionic strength and carbonate on the Ca-P coating formation from SBF× 5 solution | |
| Blind et al. | Characterization of hydroxyapatite films obtained by pulsed-laser deposition on Ti and Ti-6AL-4v substrates | |
| US5242706A (en) | Laser-deposited biocompatible films and methods and apparatuses for producing same | |
| Wang et al. | Structural characterization of pulsed laser-deposited hydroxyapatite film on titanium substrate | |
| Ong et al. | Post-deposition heat treatments for ion beam sputter deposited calcium phosphate coatings | |
| Zeng et al. | XPS, EDX and FTIR analysis of pulsed laser deposited calcium phosphate bioceramic coatings: the effects of various process parameters | |
| Van Dijk et al. | Influence of annealing temperature on RF magnetron sputtered calcium phosphate coatings | |
| Singh et al. | Excimer laser deposition of hydroxyapatite thin films | |
| Russell et al. | Chemical and structural evolution of sol‐gel‐derived hydroxyapatite thin films under rapid thermal processing | |
| Lee et al. | Biological performance of calcium phosphate films formed on commercially pure Ti by electron-beam evaporation | |
| Jung et al. | Surface characteristics of a novel hydroxyapatite-coated dental implant | |
| Wolke et al. | Stability of radiofrequency magnetron sputtered calcium phosphate coatings under cyclically loaded conditions | |
| Park et al. | Effect of magnesium and calcium phosphate coatings on osteoblastic responses to the titanium surface | |
| Ballo et al. | Bone response to physical‐vapour‐deposited titanium dioxide coatings on titanium implants | |
| EP2827915B1 (en) | A coating comprising strontium for body implants | |
| Ong et al. | Properties of calcium phosphate coatings before and after exposure to simulated biological fluid | |
| Lee et al. | Industrial application of ion beam assisted deposition on medical implants | |
| Ergün et al. | Effect of acid passivation and H2 sputtering pretreatments on the adhesive strength of sol–gel derived Hydroxyapatite coating on titanium surface | |
| Blalock et al. | A study on microstructure and properties of calcium phosphate coatings processed using ion beam assisted deposition on heated substrates | |
| Coelho et al. | Histomorphometric evaluation of a nanothickness bioceramic deposition on endosseous implants: a study in dogs | |
| Peraire et al. | Biological stability and osteoconductivity in rabbit tibia of pulsed laser deposited hydroxylapatite coatings | |
| Verestiuc et al. | Chemical growth of calcium phosphate layers on magnetron sputtered HA films |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: NOBEL BIOCARE AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HALL, JAN;KROZER, ANATOL;THOMSEN, PETER;SIGNING DATES FROM 19991201 TO 19991209;REEL/FRAME:028028/0192 |
|
| AS | Assignment |
Owner name: NOBEL BIOCARE SERVICES AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOBEL BIOCARE AB;REEL/FRAME:028140/0176 Effective date: 20100915 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |